Fiche publication
Date publication
juin 2026
Journal
PET clinics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr VERGER Antoine
Tous les auteurs :
Guedj E, Verger A, Horowitz T
Lien Pubmed
Résumé
Subjective cognitive complaints are heterogeneous and may occur with normal, subtle, or objectively abnormal cognitive testing. Fluorodeoxyglucose (FDG) PET can help explore their metabolic substrate, particularly in subjective cognitive decline within the Alzheimer's disease continuum. In mild traumatic brain injury and long coronavirus disease (COVID), available studies suggest possible metabolic-network abnormalities but involve more heterogeneous populations and should be interpreted cautiously within multimodal, clinically characterized frameworks.
Mots clés
Diaschisis, FDG PET, Hypometabolism, Long COVID, Metacognition, Mild traumatic brain injury, Preclinical Alzheimer’s disease, Subjective cognitive complaints
Référence
PET Clin. 2026 06 22;:
